Subsequently, IMmotion151 met its primary endpoint of improved PFS in PD-L1-positive patients (≥ 1% tumor-infiltrating immune cells [IC]) treated with atezolizumab plus bevacizumab across all MSKCC risk groups compared to sunitinib [51]. Here, CD274 is linked to neoplasm.